The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients. / Jordan, Alexander; Sivapalan, Pradeesh; Eklöf, Josefin; Vestergaard, Jakob B.; Meteran, Howraman; Saeed, Mohamad Isam; Biering-Sørensen, Tor; Løkke, Anders; Seersholm, Niels; Jensen, Jens Ulrik Stæhr.

I: Biomedicines, Bind 9, Nr. 10, 1492, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Jordan, A, Sivapalan, P, Eklöf, J, Vestergaard, JB, Meteran, H, Saeed, MI, Biering-Sørensen, T, Løkke, A, Seersholm, N & Jensen, JUS 2021, 'The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients', Biomedicines, bind 9, nr. 10, 1492. https://doi.org/10.3390/biomedicines9101492

APA

Jordan, A., Sivapalan, P., Eklöf, J., Vestergaard, J. B., Meteran, H., Saeed, M. I., Biering-Sørensen, T., Løkke, A., Seersholm, N., & Jensen, J. U. S. (2021). The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients. Biomedicines, 9(10), [1492]. https://doi.org/10.3390/biomedicines9101492

Vancouver

Jordan A, Sivapalan P, Eklöf J, Vestergaard JB, Meteran H, Saeed MI o.a. The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients. Biomedicines. 2021;9(10). 1492. https://doi.org/10.3390/biomedicines9101492

Author

Jordan, Alexander ; Sivapalan, Pradeesh ; Eklöf, Josefin ; Vestergaard, Jakob B. ; Meteran, Howraman ; Saeed, Mohamad Isam ; Biering-Sørensen, Tor ; Løkke, Anders ; Seersholm, Niels ; Jensen, Jens Ulrik Stæhr. / The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients. I: Biomedicines. 2021 ; Bind 9, Nr. 10.

Bibtex

@article{5156586237c9419c948e52304b9dd1ce,
title = "The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients",
abstract = "Psychiatric side effects are well known from treatment with systemic corticosteroids. It is, however, unclear whether inhaled corticosteroids (ICS) have psychiatric side effects in patients with COPD. We conducted a nationwide cohort study in all Danish COPD outpatients who had respiratory medicine specialist-verified COPD, age ≥40 years, and no previous cancer. Prescrip-tion fillings of antidepressants and risk of admissions to psychiatric hospitals with either depres-sion, anxiety or bipolar disorder were assessed by Cox proportional hazards models. We observed a dose-dependent increase in the risk of antidepressant-use with ICS cumulated dose (HR 1.05, 95% CI 1.03–1.07, p = 0.0472 with low ICS exposure, HR 1.10, 95% CI 1.08–1.12, p < 0.0001 with medium exposure, HR 1.15, 95% CI 1.11–1.15, p < 0.0001 with high exposure) as compared to no ICS exposure. We found a discrete increased risk of admission to psychiatric hospitals in the medium and high dose group (HR 1.00, 95% CI 0.98–1.03, p = 0.77 with low ICS exposure, HR 1.07, 95% CI 1.05–1.10, p < 0.0001 with medium exposure, HR 1.13, 95% CI 1.10–1.15, p < 0.0001 with high exposure). The association persisted when stratifying for prior antidepressant use. Thus, exposure to ICS was associated with a small to moderate increase in antidepressant-use and psychiatric admissions.",
keywords = "Anxiety, Bipolar disorder, COPD, Depression, ICS, Obstructive lung disease",
author = "Alexander Jordan and Pradeesh Sivapalan and Josefin Ekl{\"o}f and Vestergaard, {Jakob B.} and Howraman Meteran and Saeed, {Mohamad Isam} and Tor Biering-S{\o}rensen and Anders L{\o}kke and Niels Seersholm and Jensen, {Jens Ulrik St{\ae}hr}",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/biomedicines9101492",
language = "English",
volume = "9",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "10",

}

RIS

TY - JOUR

T1 - The association between use of ics and psychiatric symptoms in patients with copd—a nationwide cohort study of 49,500 patients

AU - Jordan, Alexander

AU - Sivapalan, Pradeesh

AU - Eklöf, Josefin

AU - Vestergaard, Jakob B.

AU - Meteran, Howraman

AU - Saeed, Mohamad Isam

AU - Biering-Sørensen, Tor

AU - Løkke, Anders

AU - Seersholm, Niels

AU - Jensen, Jens Ulrik Stæhr

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Psychiatric side effects are well known from treatment with systemic corticosteroids. It is, however, unclear whether inhaled corticosteroids (ICS) have psychiatric side effects in patients with COPD. We conducted a nationwide cohort study in all Danish COPD outpatients who had respiratory medicine specialist-verified COPD, age ≥40 years, and no previous cancer. Prescrip-tion fillings of antidepressants and risk of admissions to psychiatric hospitals with either depres-sion, anxiety or bipolar disorder were assessed by Cox proportional hazards models. We observed a dose-dependent increase in the risk of antidepressant-use with ICS cumulated dose (HR 1.05, 95% CI 1.03–1.07, p = 0.0472 with low ICS exposure, HR 1.10, 95% CI 1.08–1.12, p < 0.0001 with medium exposure, HR 1.15, 95% CI 1.11–1.15, p < 0.0001 with high exposure) as compared to no ICS exposure. We found a discrete increased risk of admission to psychiatric hospitals in the medium and high dose group (HR 1.00, 95% CI 0.98–1.03, p = 0.77 with low ICS exposure, HR 1.07, 95% CI 1.05–1.10, p < 0.0001 with medium exposure, HR 1.13, 95% CI 1.10–1.15, p < 0.0001 with high exposure). The association persisted when stratifying for prior antidepressant use. Thus, exposure to ICS was associated with a small to moderate increase in antidepressant-use and psychiatric admissions.

AB - Psychiatric side effects are well known from treatment with systemic corticosteroids. It is, however, unclear whether inhaled corticosteroids (ICS) have psychiatric side effects in patients with COPD. We conducted a nationwide cohort study in all Danish COPD outpatients who had respiratory medicine specialist-verified COPD, age ≥40 years, and no previous cancer. Prescrip-tion fillings of antidepressants and risk of admissions to psychiatric hospitals with either depres-sion, anxiety or bipolar disorder were assessed by Cox proportional hazards models. We observed a dose-dependent increase in the risk of antidepressant-use with ICS cumulated dose (HR 1.05, 95% CI 1.03–1.07, p = 0.0472 with low ICS exposure, HR 1.10, 95% CI 1.08–1.12, p < 0.0001 with medium exposure, HR 1.15, 95% CI 1.11–1.15, p < 0.0001 with high exposure) as compared to no ICS exposure. We found a discrete increased risk of admission to psychiatric hospitals in the medium and high dose group (HR 1.00, 95% CI 0.98–1.03, p = 0.77 with low ICS exposure, HR 1.07, 95% CI 1.05–1.10, p < 0.0001 with medium exposure, HR 1.13, 95% CI 1.10–1.15, p < 0.0001 with high exposure). The association persisted when stratifying for prior antidepressant use. Thus, exposure to ICS was associated with a small to moderate increase in antidepressant-use and psychiatric admissions.

KW - Anxiety

KW - Bipolar disorder

KW - COPD

KW - Depression

KW - ICS

KW - Obstructive lung disease

U2 - 10.3390/biomedicines9101492

DO - 10.3390/biomedicines9101492

M3 - Journal article

C2 - 34680609

AN - SCOPUS:85118339451

VL - 9

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 10

M1 - 1492

ER -

ID: 285514185